Valeant Pharmaceuticals Intl Inc (VRX) Set to Announce Quarterly Earnings on Tuesday

Wells Fargo & Company restated an underperform rating and set a $11.50 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, December 1st.

This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. now owns 5,917,325 shares of the specialty pharmaceutical company's stock valued at $119,175,000 after buying an additional 631,211 shares in the last quarter.

Maris lowered his fourth-quarter earnings, but writes that the results are less important than the company's longer-term deteriorating cash flow generation, high debt, and poor business trends. Laurion Capital Management LP increased its stake in Valeant Pharmaceuticals International by 0.3% in the second quarter. The stock closed down 0.4 points or 2.41% at $16.18 with 10,635,267 shares getting traded. 19 Analysts reported that the Price Target for Valeant Pharmaceuticals International, Inc. might touch $55 high while the Average Price Target and Low price Target is $22.39 and $9 respectively. Nevertheless, the shares have pushed 2.1% higher to trade at $16.52, on news Valeant Pharmaceuticals Intl Inc has increased the sales force for subsidiary Salix Pharmaceuticals by nearly 40% to "accelerate further growth", according to VRX CEO Joseph Papa. He expects the company to again say that 2017 will be stronger in the second-half of the year, much like it did in 2016. The total market capitalization remained at $5.39 billion. Valeant Pharmaceuticals International has a 12-month low of $13.00 and a 12-month high of $98.50. The firm has a 50-day moving average price of $14.58 and a 200 day moving average price of $20.70. If you are viewing this news story on another publication, it was stolen and reposted in violation of US and global copyright and trademark law.

VRX has been the subject of a number of analyst reports. Valeant Pharmaceuticals International, Inc. Stifel Nicolaus reaffirmed a "buy" rating and set a $45.00 target price on shares of Valeant Pharmaceuticals International in a research note on Thursday, February 9th. Deutsche Bank AG set a $24.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a research report on Sunday, November 20th.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded up 2.561% during midday trading on Tuesday, hitting $14.615. Finally, Barclays PLC cut their target price on Valeant Pharmaceuticals International from $34.00 to $20.00 and set an "equal weight" rating for the company in a research note on Friday, February 10th. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have given a buy rating to the company.

When it comes to the Analysis of a Stock, Price Target plays a vital role.

12/12/2016 per share and the total transaction amounting to Pershing Square Capital Manage.

In related news, Director Thomas W. Sr. The disclosure for this sale can be found here. Company insiders own 16.37% of the company's stock. "The significant investments in Salix's dedicated Primary Care Physician (PCP) sales force will help us further reach patients in need of irritable bowel syndrome with diarrhea (IBS-D) treatment, and in doing so, will further accelerate growth for our company", said Valeant Chief Executive Joseph Papa. The Developed Markets segment offers over-the-counter and medical products as well as alliance and contract service revenues, in the areas of dermatology and podiatry, neurology, gastrointestinal disorders, eye health, oncology and urology, dentistry, aesthetics, and women's health.

  • Zachary Reyes